Published in PLoS One on February 16, 2017
Model systems, lipid rafts, and cell membranes. Annu Rev Biophys Biomol Struct (2004) 7.52
The HIV lipidome: a raft with an unusual composition. Proc Natl Acad Sci U S A (2006) 4.15
Novel therapies based on mechanisms of HIV-1 cell entry. N Engl J Med (2003) 3.32
Increasing molecular diversity of secreted phospholipases A(2) and their receptors and binding proteins. Biochim Biophys Acta (2000) 1.76
Design and evaluation of sifuvirtide, a novel HIV-1 fusion inhibitor. J Biol Chem (2008) 1.74
Differential roles of ionic, aliphatic, and aromatic residues in membrane-protein interactions: a surface plasmon resonance study on phospholipases A2. Biochemistry (2001) 1.69
Membrane lipid phase as catalyst for peptide-receptor interactions. Proc Natl Acad Sci U S A (1986) 1.61
Lipids and membrane microdomains in HIV-1 replication. Virus Res (2009) 1.51
Rapid emergence of enfuvirtide resistance in HIV-1-infected patients: results of a clonal analysis. J Acquir Immune Defic Syndr (2006) 1.49
Surface plasmon resonance in protein-membrane interactions. Chem Phys Lipids (2006) 1.38
Exploring peptide membrane interaction using surface plasmon resonance: differentiation between pore formation versus membrane disruption by lytic peptides. Biochemistry (2003) 1.33
Two-step membrane binding by Equinatoxin II, a pore-forming toxin from the sea anemone, involves an exposed aromatic cluster and a flexible helix. J Biol Chem (2002) 1.20
Identification of a critical motif for the human immunodeficiency virus type 1 (HIV-1) gp41 core structure: implications for designing novel anti-HIV fusion inhibitors. J Virol (2008) 1.20
SC29EK, a peptide fusion inhibitor with enhanced alpha-helicity, inhibits replication of human immunodeficiency virus type 1 mutants resistant to enfuvirtide. Antimicrob Agents Chemother (2008) 1.15
Inhibiting HIV-1 entry with fusion inhibitors. Curr Med Chem (2003) 1.13
Electrostatically constrained alpha-helical peptide inhibits replication of HIV-1 resistant to enfuvirtide. Int J Biochem Cell Biol (2008) 1.12
The hydrophobic pocket contributes to the structural stability of the N-terminal coiled coil of HIV gp41 but is not required for six-helix bundle formation. Biochemistry (2003) 1.09
Human immunodeficiency virus type 1 Nef protein modulates the lipid composition of virions and host cell membrane microdomains. Retrovirology (2007) 1.08
Role of the ectodomain of the gp41 transmembrane envelope protein of human immunodeficiency virus type 1 in late steps of the membrane fusion process. J Virol (2004) 1.07
In vitro selection and characterization of HIV-1 variants with increased resistance to sifuvirtide, a novel HIV-1 fusion inhibitor. J Biol Chem (2010) 1.03
HIV fusion inhibitor peptide T-1249 is able to insert or adsorb to lipidic bilayers. Putative correlation with improved efficiency. J Am Chem Soc (2004) 0.95
Putative role of membranes in the HIV fusion inhibitor enfuvirtide mode of action at the molecular level. Biochem J (2004) 0.94
Lipid membrane-induced optimization for ligand-receptor docking: recent tools and insights for the "membrane catalysis" model. Eur Biophys J (2005) 0.90
Use of optical biosensors for the study of mechanistically concerted surface adsorption processes. Anal Biochem (2001) 0.89
Sifuvirtide screens rigid membrane surfaces. establishment of a correlation between efficacy and membrane domain selectivity among HIV fusion inhibitor peptides. J Am Chem Soc (2008) 0.88
Conjugation of cholesterol to HIV-1 fusion inhibitor C34 increases peptide-membrane interactions potentiating its action. PLoS One (2013) 0.88
Design of an engineered N-terminal HIV-1 gp41 trimer with enhanced stability and potency. Protein Sci (2008) 0.87
Identification of minimal sequence for HIV-1 fusion inhibitors. Bioorg Med Chem (2008) 0.84
Unravelling the molecular basis of the selectivity of the HIV-1 fusion inhibitor sifuvirtide towards phosphatidylcholine-rich rigid membranes. Biochim Biophys Acta (2010) 0.78
Using Surface Plasmon Resonance to Quantitatively Assess Lipid-Protein Interactions. Methods Mol Biol (2016) 0.77
Pharmacokinetics of sifuvirtide in treatment-naive and treatment-experienced HIV-infected patients. J Pharm Sci (2014) 0.77